WR 279,396

DRUG4 trials

Sponsors

U.S. Army Medical Research and Development Command, Assistance Publique - Hôpitaux de Paris

Conditions

Cutaneous LeishmaniasisLeishmaniasis, Cutaneous

Phase 2

Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World

CompletedNCT00703924

U.S. Army Medical Research and Development CommandCutaneous Leishmaniasis

Start: 2003-03-31End: 2005-11-30Updated: 2017-05-30

Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis

TerminatedNCT01140191

U.S. Army Medical Research and Development CommandLeishmaniasis, Cutaneous

Start: 2013-09-30End: 2014-09-30Updated: 2019-11-22

WR 279,396 for the Treatment of Cutaneous Leishmaniasis

CompletedNCT01988909

Assistance Publique - Hôpitaux de ParisCutaneous Leishmaniasis

Start: 2013-09-30End: 2015-12-31Updated: 2017-01-25

Phase 3

Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama

CompletedNCT01790659

U.S. Army Medical Research and Development CommandCutaneous Leishmaniasis

Start: 2013-05-31End: 2016-01-31Updated: 2018-02-14

Related Papers

WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study.

2009-05-0558 citations